{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:02:51Z","timestamp":1792324971655,"version":"4.4.0"},"reference-count":227,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.antiviral.2013.11.008","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T07:03:09Z","timestamp":1385190189000},"page":"119-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Chutes and ladders in hepatitis C nucleoside drug development"],"prefix":"10.1016","volume":"102","author":[{"given":"Steven J.","family":"Coats","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel C.","family":"Garnier-Amblard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Amblard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ehteshami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Amiralaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien R.L.","family":"Boucle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Bondada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadd R.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish N.","family":"Chavre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoman","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.11.008_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-8278(05)81505-3","article-title":"Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial","volume":"42","author":"Afdahl","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0010","unstructured":"Ahmed, H.A., Alfredson, T.V., Birudaraj, K., Brandl, M.T., Phuapradit, W., Shah, N.H., Stefanidis, D., 2007. HCV prodrug formulation. PCT Int. Appl., WO 2007068615."},{"key":"10.1016\/j.antiviral.2013.11.008_b0015","unstructured":"Alfredson, T., Sarma, K., Brandl, M., Larrabee, S., Wu, X., Tu, Y., Liu, H., Smith, D., Birudaraj, R., Li, F., Tran, T., Hadig, X., Hill, G., Daley, R., Blue, D., Berger, N., Symons, J., Cammack, N., Ipe, D., Berns, H., Lakatos, I., Swallow, S., Klumpp, K., 2006. Design and evaluation of novel HCV polymerase inhibitor prodrugs with enhanced oral bioavailability. AAPS Annual Meeting, San Antonio, TX."},{"key":"10.1016\/j.antiviral.2013.11.008_b0020","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/AAC.00444-08","article-title":"Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479","volume":"52","author":"Ali","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0025","doi-asserted-by":"crossref","first-page":"e1003030","DOI":"10.1371\/journal.ppat.1003030","article-title":"Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependant nuclear transcription to antiviral ribonucleosides","volume":"8","author":"Arnold","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.11.008_b0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0169-409X(96)00415-2","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"22","author":"Artursson","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2013.11.008_b0035","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/AAC.00193-07","article-title":"Pharmacokinetics of the antiviral agent \u03b2-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine in rhesus monkeys","volume":"51","author":"Asif","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.11.008_b0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1478-3231.2011.02699.x","article-title":"Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow","volume":"32","author":"Asselah","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2013.11.008_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/095632020801900104","article-title":"Combinations of 2\u2032-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system","volume":"19","author":"Bassit","year":"2008","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0050","unstructured":"Beigelman, L., Blatt, L., Wang, G., 2010. Substituted nucleoside and nucleotide analogs. PCT Int. Appl., WO 2010108140."},{"key":"10.1016\/j.antiviral.2013.11.008_b0055","unstructured":"Beigelman, L., Blatt, L., Wang, G., Rajwanshi, V.K., Dyatkina, N.B., Smith, B.D., 2012a. Substituted nucleotide analogs. PCT Int. Appl., WO 2012040126."},{"key":"10.1016\/j.antiviral.2013.11.008_b0060","unstructured":"Beigelman, L., Smith, B.D., Deval, J., Rajwanshi, V.K., 2012b. Cyclic nucleotide analogs. PCT Int. Appl., WO 2012088155."},{"key":"10.1016\/j.antiviral.2013.11.008_b0065","unstructured":"Berrey, M.M., Hindes, R., Symonds, W.T., Ray, A.S., Mo, H., Hebner, C.M., 2013. Methods and compositions for treating hepatitis C virus. PCT Int. Appl., WO 2013066748."},{"key":"10.1016\/j.antiviral.2013.11.008_b0070","unstructured":"BMS, 2012. A follow-up evaluation for safety in subjects who participated in a phase 1 study with BMS-986094 (INX-08189). Clinical trial NCT017322848. Retrieved from: <http:\/\/clinicaltrials.gov\/show\/NCT01732848>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0075","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3851\/IMP1667","article-title":"Advances in nucleoside monophosphate prodrugs as anti-hepatitis C virus","volume":"15","author":"Bobeck","year":"2010","journal-title":"Agents Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.11.008_b0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/03639040701836636","article-title":"Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability","volume":"34","author":"Brandl","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.antiviral.2013.11.008_b0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543780902854194","article-title":"Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues","volume":"18","author":"Brown","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2013.11.008_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cld.2009.05.001","article-title":"HCV NS5B polymerase inhibitors","volume":"13","author":"Burton","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2013.11.008_b0095","unstructured":"Butler, T., Cho, A., Graetz, B.R., Kim, C.U., Metobo, S.E., Saunders, O.L., Waltman, A.W., Xu, J., Zhang, L., 2011. Processes and intermediates for the preparation of 1\u2032-substituted carba-nucleosides. PCT Int. Appl., WO 2011035250."},{"key":"10.1016\/j.antiviral.2013.11.008_b0100","unstructured":"Butler, T., Cho, A., Kim, C.U., Saunders, O.L., Zhang, L., 2009. 1\u2032-Substituted carba-nucleoside analogs for antiviral treatment. PCT Int. Appl., WO 2009132135."},{"key":"10.1016\/j.antiviral.2013.11.008_b0105","unstructured":"Cedilote, M., Cleary, T.P., Zhang, P., 2008. Alternate process for preparing 3,5-O-micron-acyl-2-fluoro-2-C-methyl-d-ribono-gamma-lactone. PCT Int. Appl., WO 2008090046."},{"key":"10.1016\/j.antiviral.2013.11.008_b0110","unstructured":"Chamberlain, S., Hutchins, J., Medela, K., McGuigan, C., Vernachio, J., Aljarah, M., Gilles, A., 2010. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections. PCT Int. Appl., WO 2010081082."},{"key":"10.1016\/j.antiviral.2013.11.008_b0115","unstructured":"Cho, A., Kim, C.U., Metobo, S., Ray, A.S., Xu, J., 2011a. 2\u2032-Fluoro substituted carba-nucleoside analogs for antiviral treatment. PCT Int. Appl., WO 2011035231."},{"key":"10.1016\/j.antiviral.2013.11.008_b0120","unstructured":"Cho, A., Kim, C.U., Ray, A.S., Zhang, L., 2011b. 1\u2032-Substituted-carba-nucleoside prodrugs for antiviral treatment. PCT Int. Appl., WO 2011150288."},{"key":"10.1016\/j.antiviral.2013.11.008_b0125","unstructured":"Cho, A., Wolckenhauer, S.A., 2011. Methods for the preparation of diastereomerically pure phosphoramidate prodrugs. PCT Int. Appl., WO 2012012465."},{"key":"10.1016\/j.antiviral.2013.11.008_b0130","doi-asserted-by":"crossref","DOI":"10.1021\/jm400201a","article-title":"Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients","author":"Cho","year":"2013","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.antiviral.2013.11.008_b0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derivied from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.11.008_b0140","unstructured":"Chun, B.-K., Clark, J., Sarma, K., Wang, P., 2007. Antiviral nucleosides. PCT Int. Appl., WO 2007065829."},{"key":"10.1016\/j.antiviral.2013.11.008_b0145","unstructured":"Chun, B.-K., Du, J., Rachakonda, S., Ross, B.S., Sofia, M.J., Pamulapati Reddy, G., Chang, W., Zhang, H.R., Nagarathnam, D., 2010. Synthesis of purine nucleosides. PCT Int. Appl., WO 2010075554."},{"key":"10.1016\/j.antiviral.2013.11.008_b0150","unstructured":"Clark, J., 2005. Modified fluorinated nucleoside analogues. PCT Int. Appl., WO 2005003147."},{"key":"10.1016\/j.antiviral.2013.11.008_b0155","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1021\/jm0502788","article-title":"Design, synthesis, and antiviral activity of 2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine, a potent inhibitor of hepatitis C virus replication","volume":"48","author":"Clark","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0160","unstructured":"Cleary, D., Reynolds, C.J., Berrey, M.M., Hindes, R.G., Symonds, W.T., Ray, A.S., Mo, H., Hebner, C.M., Oliyai, R., Zia, V., Stefanidis, D., Pakdaman, R., Casteel, M.J., 2013. Compositions and methods for treating hepatitis C virus. PCT Int. Appl., WO 2013082003."},{"key":"10.1016\/j.antiviral.2013.11.008_b0165","unstructured":"Connolly, T.J., Durkin, K., Sarma, K., Zhu, J., 2005. Processes for preparing 4\u2032azido nucleoside derivatives. PCT Int. Appl., WO 05000864."},{"key":"10.1016\/j.antiviral.2013.11.008_b0170","unstructured":"Cretton-Scott, E., Gupta, K., Hernandez-Santiago, B., Larsson, M., 2010. Compounds and pharmaceutical compositions for the treatment of viral infections. PCT Int. Appl., WO 2010014134."},{"key":"10.1016\/j.antiviral.2013.11.008_b0175","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(08)60590-5","article-title":"In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication","volume":"48","author":"Cretton-Scott","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0180","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)05413-5","article-title":"Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C","volume":"350","author":"Darby","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.11.008_b0185","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/jlts.2003.50073","article-title":"Projecting future complications of chronic hepatitis C in the United States","volume":"9","author":"Davis","year":"2003","journal-title":"Liver Transpl."},{"key":"10.1016\/j.antiviral.2013.11.008_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs \u2013 the development of successful prodrug strategies for antiviral chemotherapy","volume":"146","author":"De Clercq","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0195","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nature04080","article-title":"Challenges and successes in developing new therapies for hepatitis C","volume":"436","author":"De Francesco","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.11.008_b0200","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/AAC.01262-12","article-title":"Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects","volume":"57","author":"Denning","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0205","unstructured":"Devos, R.R., Hobbs, C.J., Jiang, W.-R., Martin, J.A., Merrett, J.H., Najera, I., Shimma, N., Tsukuda, T., 2002. 4\u2032-Substituted nucleosides. PCT Int. Appl., WO 02100415."},{"key":"10.1016\/j.antiviral.2013.11.008_b0210","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","article-title":"A pilot study of ribavirin therapy for chronic hepatitis C","volume":"16","author":"Di Bisceglie","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0215","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/S0168-8278(06)80736-1","article-title":"Ealy clearance of HCV RNA with valopicitabine (NM283) plus Peg-interferon in treatment-na\u00efve patients with HCV-1 infection: first results from a phase IIb trial","volume":"44","author":"Dieterich","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0220","unstructured":"Du, J., Nagarathnam, D., Pamulapati Reddy, G., Ross, B.S., Sofia, M.J., 2009. Nucleoside cyclicphosphates. PCT Int. Appl., WO 2009152095."},{"key":"10.1016\/j.antiviral.2013.11.008_b0225","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3851\/IMP2127","article-title":"New antiviral therapies in the management of HCV infection","volume":"17","author":"Farnik","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2013.11.008_b0230","doi-asserted-by":"crossref","unstructured":"Fenaux, M., Cheng, G., Mabery, E., Ku, K., Eng, S., Vela, J., Feng, J., Delaney, W., Mo, H., Ray, A., Zhong, W., 2011. GS-6620, A novel anti-hepatitis C Virus nucleotide prodrug, has a high in vitro barrier to resistance. 46th Annual Meeting of the European Association for the Study of the Liver (EALS), Berlin, Germany.","DOI":"10.1016\/S0168-8278(11)61207-5"},{"key":"10.1016\/j.antiviral.2013.11.008_b0235","unstructured":"Fishman, S., Childs, K., Dieterich, D., Carriero, D., Uriel, A., Mullen, M., Factor, S., Fierer, D., Branch, A., 2009. Age and risky behaviors of HIV-infected men with acute HCV infection in New York City are similar, but not identical, to those in a European outbreak. In: 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada."},{"key":"10.1016\/j.antiviral.2013.11.008_b0240","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0245","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.antiviral.2011.05.003","article-title":"Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661","volume":"91","author":"Furman","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.11.008_b0250","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11894-012-0305-1","article-title":"Hepatitis C: management of side effects in the era of direct-acting antivirals","volume":"15","author":"Gaetano","year":"2013","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.antiviral.2013.11.008_b0255","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0168-8278(10)60040-2","article-title":"Sustained virologic response (SVR) following RG7128 1500 mg BID\/Peg-IFN\/RBV for 28 days in HCV genotype 2\/3 prior nonresponders","volume":"52","author":"Gane","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0260","unstructured":"Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Pang, P.S., Symonds, W.T., 2013a. 20th Conference on Retroviruses and Opportunistic Infections (CROI, March 3\u20136 2013), Atlanta, GA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.11.008_b0270","unstructured":"Gane, E.J., Stedman, C.A., Hyland, R.H., Pang, P.S., Sorensen, R.D., Symonds, W.T., Hindes, R.D., Berrey, M.M., 2012. Once daily sofosbuvir (GS-7977) regimens in HCV genotype 1\u20133: the ELECTRON trial. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jlac.18530870206","article-title":"Untersuchungen \u00fcber die wasserfreien organischen S\u00e4uren","volume":"87","author":"Gerhardt","year":"1853","journal-title":"Ann. Chem. Pharma."},{"key":"10.1016\/j.antiviral.2013.11.008_b0280","unstructured":"Ghosn, J., Larsen, C., Piroth, L., Duval, X., Auperin, I., Delarocque-Astagneau, E., Gervais, A., Alric, L., Pol, S., Chaix, M.-L., 2009. Evidence for ongoing epidemic sexual transmission of HCV (2006 to 2007) among HIV-1-infected men who have sex with men: France. In: 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada."},{"key":"10.1016\/j.antiviral.2013.11.008_b0285","unstructured":"Gilead, 2011. GS-7977 alone or with ribavirin for hepatitis C. Clinical trial NCT01441180. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01441180?term=01441180&rank=01441181>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0290","unstructured":"Gilead, 2012. Gilead announces sustained virologic response rate of 78% from phase 3 study of sofosbuvir for genotype 2\/3 hepatitis C infected patients. Press release. Retrieved from: <http:\/\/www.gilead.com\/news\/press-releases\/2012\/11\/gilead-announces-sustained-virologic-response-rate-of-78-from-phase-3-study-of-sofosbuvir-for-genotype-23-hepatitis-c-infected-patients>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0295","unstructured":"Gilead, 2013a. Gilead announces sustained virologic response rates from two phase 3 studies of sofosbuvir for hepatitis C. Press release. Retrieved from: <http:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1780873>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0300","unstructured":"Gilead, 2013b. Gilead provides update on hepatitis C development programs. Press release. Retrieved from: <http:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1771657>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0305","unstructured":"Gilead, 2013c. Gilead submits new drug application to U.S. FDA for Sofosbuvir for the treatment of Hepatitis C. Press release. Retrieved from: <http:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1804362>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0310","unstructured":"Gilead, 2013d. Gilead\u2019s Sofosbuvir for hepatitis C meets primary endpoint in fourth pivotal phase 3 study. Press release. Retrieved from: <http:\/\/www.gilead.com\/news\/press-releases\/2013\/2\/gileads-sofosbuvir-for-hepatitis-c-meets-primary-endpoint-in-fourth-pivotal-phase-3-study>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0315","unstructured":"Gilead, 2013e. Safety and efficacy of sobosbuvir\/ledipasvir fixed-dose combination +\/\u2212 ribavirin for the treatment of HCV (ION-3). Clinical trial NCT01851330. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01851330?term=ion-01851333&rank=01851331>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-8278(04)90096-7","article-title":"First clinical results for a novel antiviral treatment for hepatitis C: a phase I\/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283","volume":"S1","author":"Godofsky","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm0400101","article-title":"Control of hepatitis C: a medicinal chemistry perspective","volume":"48","author":"Gordon","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0330","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.bmcl.2007.02.030","article-title":"Cyclic monophosphate prodrugs of base-modified 2\u2032-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication","volume":"17","author":"Gunic","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.11.008_b0335","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.12063","article-title":"Best strategies for global HCV eradication","volume":"33","author":"Hagan","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2013.11.008_b0340","unstructured":"Harrington, P.J., Hilbrand, S., Sarma, K., 2008. Process for preparation of 4\u2032-azido cytidine derivatives. PCT Int. Appl., WO 2008071571."},{"key":"10.1016\/j.antiviral.2013.11.008_b0345","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1021\/jo961893+","article-title":"A short, flexible route toward 2\u2032-C-branched ribonucleosides","volume":"62","author":"Harry-O\u2019kuru","year":"1997","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0350","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1021\/jm701260b","article-title":"Prodrugs of phosphates and phosphonates","volume":"51","author":"Hecker","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0355","doi-asserted-by":"crossref","unstructured":"Hezode, C., Dorival, C., Zoulim, F., Poynard, T., Mathurin, P., Pol, S., Larrey, D., Cacoub, P., De Ledinghen, V., Bourli\u00e8re, M., Bernard, P.H., Riachi, G., Alric, L., Samuel, D., Barthe, Y., Fontaine, H., Carrat, F., Bronowicki, J.-P., 2012. Safety of telaprevir or boceprevir in combination with peginterferon alfa\/ribavirin, in cirrhotic non responders. First results of the french early access program (ANRS CO20-CUPIC). International Liver Congress 2012. Retrieved from: <http:\/\/mobile.ilcapp.eu\/EASL_161\/poster_23756\/program.aspx>.","DOI":"10.1016\/S0168-8278(12)60022-1"},{"key":"10.1016\/j.antiviral.2013.11.008_b0360","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C: the clinical spectrum of disease","volume":"26","author":"Hoofnagle","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0365","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.antiviral.2006.06.001","article-title":"Recent development of therapeutics for chronic HCV infection","volume":"71","author":"Huang","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.11.008_b0370","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1345\/aph.1G263","article-title":"Chronic hepatitis C virus management: 2000\u20132005 update","volume":"40","author":"Hughes","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0375","doi-asserted-by":"crossref","first-page":"A28","DOI":"10.1016\/j.antiviral.2009.02.047","article-title":"In vitro activity and in vivo pharmacokinetics of highly potent phosphoramidate nucleoside analogue inhibitors of hepatitis C NS5B","volume":"82","author":"Hutchins","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.11.008_b0380","unstructured":"Idenix, 2007. Valopicitabine development program placed on clinical hold in the United States. Press release. Retrieved from: <http:\/\/www.thefreelibrary.com\/Valopicitabine+Development+Program+Placed+on+Clinical+Hold+in+the...-a0166344307>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0385","unstructured":"Idenix, 2008a. Double-blind, dose-escalating study of IDX184 in chronic hepatitis C treatment-na\u00efve subjects. Clinical trial NCT00807001. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00807001?term=idx00807184&rank=00807005>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0390","unstructured":"Idenix, 2008b. Single-dose escalation study of IDX184 in healthy volunteers. Clinical trial NCT00730431. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00730431?term=idx00730184&rank=00730436>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0395","unstructured":"Idenix, 2009. Safety and antiviral activity of IDX184 in combination with pegylated interferon and ribavirin. Clinical trial NCT01011166. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01011166?term=idx01011184&rank=01011161>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0400","unstructured":"Idenix, 2010. A drug-drug interaction study evaluating the combination of IDX320 and IDX184 in healthy subjects. Clinical trial NCT01157104. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01157104?term=idx01157184&rank=01157102>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0405","unstructured":"Idenix, 2011a. Idenix pharmaceuticals provides updates on three clinical development programs. Press release. Retrieved from: <http:\/\/ir.idenix.com\/releasedetail.cfm?ReleaseID=611432>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0410","unstructured":"Idenix, 2011b. A open-label study to evaluate the relative bioavailability of IDX184 and food effect in healthy male subjects. Clinical trial NCT01335607. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01335607?term=idx01335184&rank=01335603>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0415","series-title":"Aspirin: The Remarkable Story of a Wonder Drug","author":"Jeffreys","year":"2005"},{"key":"10.1016\/j.antiviral.2013.11.008_b0420","first-page":"360A","article-title":"High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1\/4 patients treated with RG7128 plus Peg-IFN alfa-2a (40KD)\/RBV: planned week 12 interim analysis from the PROPEL study","volume":"52","author":"Jensen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0425","unstructured":"Johansson, N.-G., Kalayanov, G., Martin, J.A., Smith, B.D., Winqvist, A., 2008. HCV Nucleoside inhibitor. PCT Int. Appl., WO 2008043704."},{"key":"10.1016\/j.antiviral.2013.11.008_b0430","unstructured":"Jonckers, T.H., Raboisson, P., Vandyck, K., Pelcman, M., Sund, B.C., Wahling, H.J., Passos Pinho, P.M., Winqvist, A., Nilsson, K.M., 2011. Phosphoramidate derivatives of nucleosides. PCT Int. Appl., WO 2011039221."},{"key":"10.1016\/j.antiviral.2013.11.008_b0435","unstructured":"Keicher, J.D., Roberts, C.D., Dyatkina, N.B., 2005. Nucleoside compounds for treating viral infections. PCT Int. Appl., US 0107312."},{"key":"10.1016\/j.antiviral.2013.11.008_b0440","doi-asserted-by":"crossref","first-page":"39980","DOI":"10.1074\/jbc.M110.178582","article-title":"Ribonucleoside triphosphates as substrate of human immunodefficency virus type 1 reverse transcriptase in human macrophages","volume":"285","author":"Kennedy","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0445","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M510195200","article-title":"The novel nucleoside analog R1479 (4\u2032-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture","volume":"281","author":"Klumpp","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0450","series-title":"Antiviral Drugs: From Basic Discovery through Clinical Trials","article-title":"Discovery and clinical evaluation of the nucleoside analog balapiravir (R1626) for the treatment of HCV infection","author":"Klumpp","year":"2011"},{"key":"10.1016\/j.antiviral.2013.11.008_b0455","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2174\/156802607781212211","article-title":"Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase","volume":"7","author":"Koch","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jlac.18601130120","article-title":"Uber Synthese der Salicyls\u00e4ure","volume":"113","author":"Kolbe","year":"1860","journal-title":"Ann. Chem. Pharma."},{"key":"10.1016\/j.antiviral.2013.11.008_b0465","unstructured":"Kolykhalov, A., Chamberlain, S., Gorovits, E., Hutchins, J., Liu, Y., Muhammad, J., Raja, N., Vernachio, J., Henson, G., Madela, K., Gilles, A., Mcguigan, C., Patti, J., 2009. In vitro characterization of INX-189, a highly potent phosphoramidate nucleoside analogue inhibitor of HCV. HEP DART: Frontiers in Drug Development for Viral Hepatitis, Hawaii, USA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0470","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-na\u00efve patients with hepatitis C geotype-1 infection (ATOMIC): an open-label, randomised, multicenter phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.11.008_b0475","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/AAC.01521-12","article-title":"Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection","volume":"56","author":"Lalezari","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0480","unstructured":"Lalezari, J., Asmuth, D., Casiro, A., Vargas, H., Patrick, G.D., Liu, W., Pietropaolo, K., Zhou, X.J., Sullivan-Bolyai, J., Mayers, D., 2009. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. In: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0485","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2552","article-title":"IDX184 in combination with peginterferon alfa-2a and ribavirin for two weeks in treatment-na\u00efve patients with chronic hepatitis C","author":"Lalezari","year":"2013","journal-title":"Antivir. Ther"},{"key":"10.1016\/j.antiviral.2013.11.008_b0490","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(10)61204-4","article-title":"Antiviral activity, pharmacokinetics and safety of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-na\u00efve HCV genotype 1-infected subjects","volume":"52","author":"Lalezari","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0495","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0500","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1016\/j.antiviral.2011.03.004","article-title":"In vitro selection of HCV replicons with reduced sensitivity to PSI-352938, a cyclicphosphate prodrug of \u03b2-d-2\u2032-\u03b1-F-2\u2032-\u03b2-C-methylguanosine","volume":"90","author":"Lam","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.11.008_b0505","unstructured":"Lawitz, E., Box, T., Pruitt, M., Rodriguez-Torres, M., Nguyen, T., Lalezari, J., Vargas, H., Goff, J., Hinestrosa, F., Luketic, V., Mehra, P., Dubuc-Patrick, G., Donovan, E., Chen, J., Pietropaolo, K., Zhou, X.J., Sullivan-Bolyai, J.Z., Mayers, D., 2012a. High rates of rapid virologic response (RVR) and complete early virologic response (cEVR) with IDX184, pegylated interferon and ribavirin in genotype 1 HCV-infected subjects: interim results. Annual Meeting of the American Association for the Study of Liver Diseases (AALSD, Nov. 9\u201313 2012), Boston, MA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0510","unstructured":"Lawitz, E., Ghalib, R., Rodriguez-Torres, M., Nguyen, T., Lalezari, J., Vargas, H., Goff, J., Hinestrosa, F., Luketic, V., Mehra, P., Dubuc-Patrick, G., Donovan, E., Chen, J., Pietropaolo, K., Zhou, X.J., Sullivan-Bolyai, J.Z., Mayers, D., 2013a. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of simeprevir+sofosbuvir with or without ribavirin in heptitis C virus GT1 null responders. In: 20th Conference on Retroviruses and Opportunistic Infections (CROI, March 3\u20136 2013). Paper #155LB, Atlanta, GA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0515","doi-asserted-by":"crossref","unstructured":"Lawitz, E., Hill, J., Marbury, T., Hazan, L., Gruener, D., Webster, L., Majauskas, R., Morrison, R., DeMicco, M., German, P., Stefanidis, D., Svaroskaia, E., Arterburm, S., Ray, A., Rossi, S., McHutchison, J., Rodriguez-Torres, M., 2012b. GS-6620, a liver-targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment-naive chronic HCV genotype 1 subjects. 47th Annual Meeting of the European Association for the study of the Liver, Barcelona, Spain.","DOI":"10.1016\/S0168-8278(12)61200-8"},{"key":"10.1016\/j.antiviral.2013.11.008_b0520","first-page":"566A","article-title":"BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in treatment-na\u00efve HCV-genotype 2\/3 patients compared to peginterferon alfa-2a and ribavirin: week 12 results","volume":"56","author":"Lawitz","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0525","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-na\u00efve patients with genotype 1, 2, and 3 hepatitis C infecton: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.11.008_b0530","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0168-8278(07)61612-2","article-title":"Clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-na\u00efve patients with HCV-1 infection: results at 24 and 28 weeks","volume":"46","author":"Lawitz","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0535","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/S0168-8278(11)61372-X","article-title":"Once daily dual-nucleotide comtination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine\/pyrimidine clinical combination data (The NUCLEAR Study)","volume":"54","author":"Lawitz","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0540","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/AAC.01263-12","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, follwoing multiple ascending doses in patients with chronic hepatitis C infection","volume":"57","author":"Lawitz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0545","first-page":"701A","article-title":"No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN\/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study","volume":"52","author":"Le Pogam","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0550","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/13543784.2010.500285","article-title":"New NS5B polymerase inhibitors for hepatitis C","volume":"19","author":"Legrand-Abravanel","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2013.11.008_b0555","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2010.02.003","article-title":"Development of novel therapies for hepatitis C","volume":"86","author":"Lemon","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.11.008_b0560","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/jps.21047","article-title":"Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting","volume":"97","author":"Li","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2013.11.008_b0565","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.1021\/jo034263y","article-title":"Synthesis of the phosphoramidite derivatives of 2\u2032-deoxy-2\u2032-C-methyl cytidine","volume":"68","author":"Li","year":"2003","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0570","unstructured":"Ligand, 2010. Roche\u2019s progress of RG7348 into phase I clinical trial triggers $6.5M milestone payment to Ligand. Press release. Retrieved from: <http:\/\/investor.ligand.com\/Investors\/News-and-Events\/Press-Releases\/Press-Release-Details\/2010\/Ligand-Completes-Acquisition-of-Metabasis\/default.aspx>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0575","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","article-title":"Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay","volume":"49","author":"Ludmerer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0580","doi-asserted-by":"crossref","first-page":"29812","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor \u03b2-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine (PSI-6130) and Identification of a novel active 5\u2032-triphosphate species","volume":"282","author":"Ma","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0585","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","article-title":"The way forward in HCV treatment\u2014finding the right path","volume":"6","author":"Manns","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2013.11.008_b0590","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.11.008_b0595","first-page":"235A","article-title":"ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-na\u00efve genotype 1 (GT1) patients","volume":"56","author":"Marcellin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0600","unstructured":"Martin, J.A., Sarma, K., Smith, B.D., Smith, M., 2004. Antiviral nucleoside derivatives. PCT Int. Appl., WO 2004046159."},{"key":"10.1016\/j.antiviral.2013.11.008_b0605","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/S0168-8278(11)61239-7","article-title":"No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects","volume":"54","author":"McCarville","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0610","unstructured":"McCarville, J.F., Li, B., Panzo, R.J., Gillum, J.M., Soubasakos, M.A., Bilello, J.P., Lallos, L.B., Seifer, M., Standring, D.N., 2010. In vitro and in vivo resistance profile of IDX184, a novel nucleotide analog for the treatment of HCV infection. In: 5th International Workshop on Hepatitis C \u2013 Resistance and New Compounds, Boston, MA."},{"key":"10.1016\/j.antiviral.2013.11.008_b0615","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.01317-07","article-title":"The hepatitis C virus replicon presents a higher barier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors","volume":"52","author":"McCown","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0620","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1021\/jm1003792","article-title":"Phosphoramidate ProTides of 2\u2032-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties","volume":"53","author":"McGuigan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0625","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1016\/j.bmcl.2010.06.094","article-title":"Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus","volume":"20","author":"McGuigan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.11.008_b0630","unstructured":"McGuigan, C., Perrone, P., 2008. Chemical compounds. PCT Int. Appl., WO 2008062206."},{"key":"10.1016\/j.antiviral.2013.11.008_b0635","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0640","unstructured":"Medivir, 2011a. Annual report. Retrieved from: <http:\/\/medivir.se\/v4\/images\/pdf\/2012\/Medivir_annualreport.pdf>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0645","unstructured":"Medivir, 2011b. Medivir announces start of phase 1a trial of the hepatitis C polymerase inhibitor TMC64128. Press release. Retrieved from: <http:\/\/www.medivir.se\/v5\/en\/uptodate\/pressrelease.cfm?releaseid=2D62DF545CEECD11&year=2011>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0650","unstructured":"Medivir, 2011c. TMC649128 enters phase 1b trial in patients chronically infected with genotype 1 hepatitis C virus. Press release. Retrieved from: <http:\/\/www.medivir.se\/v5\/en\/uptodate\/pressrelease.cfm?releaseid=1639EA2C5103B43D&year=2011>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0655","unstructured":"Medivir, 2013. Medivir announces interim results from cohort 2 of the COSMOS study evaluating simeprevir and sofosbuvir in HCV patients with METAVIR scores F3-F4. Press release. Retrieved from: <http:\/\/www.medivir.se\/v5\/en\/uptodate\/pressrelease.cfm?releaseid=FEBC5055C8C2C046&year=2013>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0660","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cld.2011.05.003","article-title":"The HCV NS5B nucleoside and non-nucleoside inhibitors","volume":"15","author":"Membreno","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2013.11.008_b0665","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1016\/j.ejmech.2009.04.043","article-title":"Cyclic phosphoramidates as prodrugs of 2\u2032-methylcytidine","volume":"44","author":"Meppen","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0670","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.00400-06","article-title":"Mechanism of activation of beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase","volume":"51","author":"Murakami","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0675","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine involves a second metabolic pathway leading to beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0680","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0685","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.coviro.2013.08.011","article-title":"Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase","volume":"3","author":"Najera","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0690","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31482-6","article-title":"Balapiravir plus peginterferon alfa-2a (4-KD)\/ribavirin in a randomized trial of heptitis C genotype 1 patients","volume":"11","author":"Nelson","year":"2012","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0695","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.11.008_b0700","first-page":"S96","article-title":"Study, pharmacokinetics (PK), and antiviral activity of RG7348, a novel Hepdirect\u2122 liver-targeted double prodrug hepatitis C virus (HCV) nucleoside polymerase inhibitor","volume":"91","author":"Nieforth","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2013.11.008_b0705","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/j.bmcl.2012.03.021","article-title":"Discovery of 4\u2032-azido-2\u2032-deoxy-2\u2032-C-methyl cytidine and prodrugs thereof: a potent inhibitor of hepatitis C virus replication","volume":"22","author":"Nilsson","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.11.008_b0710","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in Patients with unfavorable treatment characteristics","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2013.11.008_b0715","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.3748\/wjg.v18.i43.6183","article-title":"Telaprevir\/boceprevir era: from bench to bed and back","volume":"18","author":"Pan","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0720","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0168-8278(11)60462-5","article-title":"A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects","volume":"54","author":"Patti","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(03)00088-3","article-title":"Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C","volume":"59","author":"Pawlotsky","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2013.11.008_b0730","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1128\/JVI.78.11.5867-5874.2004","article-title":"Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C","volume":"78","author":"Pham","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0735","unstructured":"Pharmasset, 2009. Pharmasset nominates PSI-938 as a new nucleotide analog inhibitor of hepatitis C for Preclinical development. Press release. Retrieved from: <http:\/\/www.prnewswire.com\/news-releases\/pharmasset-nominates-psi-938-as-a-new-nucleotide-analog-inhibitor-of-hepatitis-c-for-preclinical-development-62126747.html>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0740","unstructured":"Pharmasset, 2010. Pharmasset reports positive preliminary antiviral data with PSI-938 for the treatment of hepatitis. Press release. Retrieved from: <http:\/\/www.virtualpressoffice.com\/publicsiteContentFileAccess?fileContentId=396775&fromOtherPageToDisableHistory=Y&menuName=News&sId=&sInfo>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0745","unstructured":"Pharmasset, 2011a. Pharmasset announces intent to amend QUANTUM trial. Press release. Retrieved from: <http:\/\/www.hivandhepatitis.com\/hepatitis-c\/hepatitis-c-topics\/hcv-treatment\/3412-pharmasset-halts-testing-of-hcv-polymerase-inhibitor-psi-3938-due-to-liver-problems>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0750","unstructured":"Pharmasset, 2011b. Pharmasset halts hepatitis C drug in test. The Wall Street Journal. Retrieved from: <http:\/\/online.wsj.com\/article\/SB10001424052970204553904577102383041237416.html>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0755","unstructured":"Pharmasset, 2011c. Pharmasset initiates QUANTUM, a phase 2b interferon-free trial of PSI-7977 and PSI-938 for all HCV genotypes. Press release. Retrieved from: <http:\/\/www.hivandhepatitis.com\/hepatitis-c\/hepatitis-c-topics\/hcv-treatment\/3251-pharmasset-starts-trial-of-psi-7977-and-psi-3938-oral-regimens-for-all-hcv-genotypes>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0760","unstructured":"Pharmasset, 2011d. PSI-938 receives fast track designation from the FDA for the treatment of chronic hepatitis C infection. Press release. Retrieved from: <http:\/\/www.hivandhepatitis.com\/hepatitis-c\/hepatitis-c-topics\/hcv-treatment\/3199-hcv-polymerase-inhibitor-psi-3938-gets-fast-track-status>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0765","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1081\/NCN-200060112","article-title":"NM283, an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine","volume":"24","author":"Pierra","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2013.11.008_b0770","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1016\/S0168-8278(11)61361-5","article-title":"First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon\/ribavirin in treatment-na\u00efve HCV G1\/4 patients: interim analysis from the JUMP-C trial","volume":"54","author":"Pockros","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0775","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.26275","article-title":"JUMP-C: a randomized trial of mericitabine plus peginterferon alfa-2a\/ribavirin for 24 weeks in treatment-na\u00efve HCV genotype 1\/4 patients","volume":"58","author":"Pockros","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0780","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon \u03b1-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0785","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.2174\/092986706779010270","article-title":"Prodrug approaches of nucleotides and oligonucleotides","volume":"13","author":"Poij\u00e4rvi-Virta","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0790","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/bega.1999.0071","article-title":"Natural history of HCV infection","volume":"14","author":"Poynard","year":"2000","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0795","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persitence of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"41","author":"Radkowski","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0800","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1016\/j.bmcl.2010.10.035","article-title":"2\u2032-Deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyl 3\u2032,5\u2032-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938","volume":"20","author":"Reddy","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.11.008_b0805","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1021\/jo200060f","article-title":"Stereoselective synthesis of PSI-352938: A \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyl-3\u2032,5\u2032-cyclic phosphate nucleotide prodrug for the treatment of HCV","volume":"76","author":"Reddy","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0810","first-page":"862A","article-title":"Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy","volume":"46","author":"Reddy","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0815","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.11.008_b0820","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","article-title":"Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C","volume":"48","author":"Roberts","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0825","first-page":"S98","article-title":"Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting HCV polymerase: results from a phase 1 single dose escalation trial in healthy subjects","volume":"81","author":"Robson","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2013.11.008_b0830","unstructured":"Roche, 2008. A study of HCV polymerase inhibitor prodrug in combination with PEGASYS plus COPEGUS compared with PEGASYS plus COPEGUS in patients with chronic hepatitis C genotype 1 infection. Clinical trial NCT00517439. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00517439?term=00517439&rank=00517431>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0835","unstructured":"Roche, 2010. Annual report. Retrieved from: <http:\/\/www.roche.com\/gb10e01.pdf>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0840","unstructured":"Roche, 2011a. Annual report. Retrieved from: <http:\/\/www.roche.com\/static\/app\/annual_report_2011\/_data\/pipeline\/pipeline.html>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0845","unstructured":"Roche, 2011b. Committed to innovation and profitable growth. Nine months YTD 2011 sales. Retrieved from: <http:\/\/www.roche.com\/irp3q11e.pdf>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0850","unstructured":"Roche, 2012. ANNAPURNA: a study of the combination of RO5466731, RO5190591, ritonavir and copegus (ribavirin) with or without RO5024048 in patients with chronic hepatitis c who are either treatment-na\u00efve or have previously experienced a null response to interferon-based treatment. Clinical trial NCT01628094. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01628094?term=01628094&rank=01628091>."},{"key":"10.1016\/j.antiviral.2013.11.008_b0855","first-page":"1160A","article-title":"Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEG-IFN and ribavirin: subanalysis by race\/ethnicity, weight and HCV genotype","volume":"48","author":"Rodriguez-Torres","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0860","first-page":"535A","article-title":"Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in na\u00efve genotype-1 HCV patients","volume":"54","author":"Rodriguez-Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0865","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.11.018","article-title":"Sofosbuvir (GS-7977) plus peginterferon\/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial","volume":"58","author":"Rodriguez-Torres","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0870","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1021\/jo201492m","article-title":"Synthesis of diastereomerically pure nucleotide phosphoramidates","volume":"76","author":"Ross","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0875","unstructured":"Ross, B.S., Sofia, M.J., Pamulapati Reddy, G., Rachakonda, S., Zhang, H.-R., Chun, B.-K., Wang, P., 2010. N-[(2\u2032R)-2\u2032-deoxy-2\u2032-fluoro-2\u2032-methyl-P-phenyl-5\u2032-uridylyl]-l-alanine 1-methylethyl ester and process for its production. PCT Int. Appl., WO 2010135569."},{"key":"10.1016\/j.antiviral.2013.11.008_b0880","unstructured":"Sarma, K., 2007. Selective O-acylation of nucleosides. PCT Int. Appl., US 2007066815."},{"key":"10.1016\/j.antiviral.2013.11.008_b0885","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti-hepatitis C virus drugs in development","volume":"142","author":"Schaefer","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.11.008_b0890","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/prac.18850310130","article-title":"Beitrag zur Kenntniss der Kolbe\u2019schen Salicyls\u00e4ure Synthese","volume":"31","author":"Schmitt","year":"1885","journal-title":"J. Prakt. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jlac.18691500102","article-title":"Uber Salicylverbindungen","volume":"150","author":"Schr\u00f6der","year":"1869","journal-title":"Ann. Chem. Pharma."},{"key":"10.1016\/j.antiviral.2013.11.008_b0900","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nbt0711-553","article-title":"New merck and vertex drugs raise standard of care in hepatitis C","volume":"29","author":"Sheridan","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0905","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nbt1112-1015","article-title":"Calamitous HCV trial casts shadow over nucleoside drugs","volume":"30","author":"Sheridan","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0910","unstructured":"Smith, B.D., Deval, J., Dyatkina, N.B., Beigelman, L., Wang, G., 2012. Substituted nucleotide analogs. PCT Int. Appl., WO 2010040127."},{"key":"10.1016\/j.antiviral.2013.11.008_b0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2007.02.004","article-title":"Design, synthesis and antiviral properties of 4\u2032-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479","volume":"17","author":"Smith","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.11.008_b0920","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3851\/IMP1797","article-title":"Nucleotide prodrugs for HCV therapy","volume":"22","author":"Sofia","year":"2011","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b0925","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b0930","unstructured":"Sofia, M.J., Du, J., Wang, P., Nagarathnam, D., 2008. Nucleoside phosphoramidate prodrugs. PCT Int. Appl., WO 2008121634."},{"key":"10.1016\/j.antiviral.2013.11.008_b0935","unstructured":"Sofia, M.J., Du, J., Wang, P., Nagarathnam, D., 2010b. Nucleoside phosphoramidates. PCT Int. Appl., WO 2010075549."},{"key":"10.1016\/j.antiviral.2013.11.008_b0940","unstructured":"Sommadossi, J.-P., Gosselin, G., Pierra, C., Perigaud, C., Peyrottes, S., 2008. Compounds and pharmaceutical compositions for the treatment of viral infections. PCT Int. Appl., WO 2008082601."},{"key":"10.1016\/j.antiviral.2013.11.008_b0945","unstructured":"Sommadossi, J.-P., La Colla, P., 2001a. Methods and compositions for treating Flaviviruses and Pesiviruses. PCT Int. Appl., WO 0192282."},{"key":"10.1016\/j.antiviral.2013.11.008_b0950","unstructured":"Sommadossi, J.-P., La Colla, P., 2001b. Methods and compositions for treating hepatitis C virus. PCT Int. Appl., WO 01090121."},{"key":"10.1016\/j.antiviral.2013.11.008_b0955","unstructured":"Sommadossi, J.-P., La Colla, P., Standring, D., Bichko, V., Qu, L., 2004a. 2\u2032-branched nucleosides and flaviridae mutation. PCT Int. Appl., WO 2004046331."},{"key":"10.1016\/j.antiviral.2013.11.008_b0960","unstructured":"Sommadossi, J.-P., La Colla, P., Storer, R., Gosselin, G., 2004b. 2\u2032 and 3\u2032-nucleoside prodrugs for treating flaviridae infections. PCT Int. Appl., WO 200400300."},{"key":"10.1016\/j.antiviral.2013.11.008_b0965","unstructured":"Sommadossi, J.-P., La Colla, P., Storer, R., Gosselin, G., 2004c. Modified 2\u2032 and 3\u2032-nucleoside prodrugs for treating flaviridae infections. PCT Int. Appl., WO 2004002999."},{"key":"10.1016\/j.antiviral.2013.11.008_b0970","unstructured":"Standring, D., 2012. IDX184 and novel nucleotides for the treatment of HCV. In: 20th International Round Table on Nucleosides, Nucleotides and Nucleic Acids, Montreal, Canada."},{"key":"10.1016\/j.antiviral.2013.11.008_b0975","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(08)60069-0","article-title":"Potent antiviral activity of second generation nucleoside inhibitors, IDX102 and IDX184, in HCV-infected chimpanzees","volume":"48","author":"Standring","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0980","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0168-8278(09)60093-3","article-title":"Antiviral activity of the liver-targeted nucleotide HCV polymerase inhibitor IDX184 correlates with trough serum levels of the nucleoside metabolite in HCV-infected chimpanzees","volume":"50","author":"Standring","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2013.11.008_b0985","unstructured":"Storer, R., Moussa, A., Chaudhuri, N., Waligora, F., 2004. Process for the production of 2-branched nucleosides. PCT Int. Appl., WO 2004052899."},{"key":"10.1016\/j.antiviral.2013.11.008_b0990","unstructured":"Stuyver, L.J., 2003. Dosing regimen for Gemcitabine HCV therapy. PCT Int. Appl., WO 03068164."},{"key":"10.1016\/j.antiviral.2013.11.008_b0995","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/095632020601700203","article-title":"Inhibition of hepatitis C replicon RNA synthesis by \u03b2-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine: a specific inhibitor of hepatitis C virus replication","volume":"17","author":"Stuyver","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b1000","first-page":"S560","article-title":"Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +\/\u2212 ribavirin, in treatment-na\u00efve patients with chronic HCV GT1, 2, or 3","volume":"56","author":"Sulkowski","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b1005","doi-asserted-by":"crossref","unstructured":"Sulkowski, M., Gardiner, D., Rodriguez-Torres, M., Reddy, K., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A., Hinestrosa, F., Thuluvath, P., Schwartz, H., Nelson, D., Eley, T., Wind-Rotolo, M., Huang, S.-P., Gao, M., McPhee, F., Sherman, D., Hindes, R., Symonds, W., Pasquinelli, C., Grasela, D., 2012b. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-na\u00efve patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 56 (suppl. 4), abstract LB-02. Annual Meeting of the American Association for the Study of Liver Diseases (AALSD, Nov. 09\u201313 2012, Boston, MA).","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"10.1016\/j.antiviral.2013.11.008_b1010","doi-asserted-by":"crossref","unstructured":"Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A.S., Hinestrosa, F., Thuluvath, P.J., Schwartz, H., Nelson, D.R., Everson, G.T., Eley, T., Wind-Rotolo, M., Huang, S.-P., Gao, M., Hernandez, D., McPhee, F., Sherman, D., Hindes, R., Symonds, W., Pasquinelli, C., Grasela, D.M., 2013. Sustained Virologic Response with daclatasvir plus sofosbuvir\u00b1ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). In: 48th Annual Meeting of the European Association for the Study of the Liver (EASL, April 24\u201328, 2013). AI4444-040 Study group, abstract 1417. Retrieved from: file:\/\/localhost\/%20http\/: <http:\/\/www.natap.org:2013:EASL:EASL_1422.htm>.","DOI":"10.1016\/S0168-8278(13)61416-6"},{"key":"10.1016\/j.antiviral.2013.11.008_b1015","unstructured":"Surleraux, D., Gosselin, G., 2011. Compounds and pharmaceutical compositions for the treatment of viral infections. PCT Int. Appl., WO 2011123586."},{"key":"10.1016\/j.antiviral.2013.11.008_b1020","unstructured":"Surleraux, D., Gosselin, G., 2012. Compounds and pharmaceutical compositions for the treatment of viral infections. PCT Int. Appl., WO 2012154321."},{"key":"10.1016\/j.antiviral.2013.11.008_b1025","unstructured":"Tibotec, B., 2011a. A trial in genotype 1 hepatitis C virus (HCV) \u2013 infected participants to determine the safety, tolerability, pharmacokinetics and antiviral activity of TMC649128, alone and combined with pegylated interferon+ribavirin. Clinical trial NCT01391117. <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01391117?term=TMC01649128&rank=01391111>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1030","unstructured":"Tibotec, P., 2011b. First in-human trial to examine safety, tolerability, and pharmacokinetics (how the drug is absorbed into the bloodstream) of increasing single oral doses of TMC649128 in healthy volunteers. Clinical trial NCT01288677. Retrieved from: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01288677?term=TMC01649128&rank=01288672>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1035","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.23808","article-title":"Is sexual contact a major mode of hepatitis C virus transmission?","volume":"52","author":"Tohme","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b1040","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","article-title":"Clinical outcomes after transfusion\u2013associated hepatitis C","volume":"332","author":"Tong","year":"1995","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.11.008_b1045","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","author":"Tong","year":"2013","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.antiviral.2013.11.008_b1050","first-page":"738","article-title":"R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C Virus","volume":"11","author":"Toniutto","year":"2008","journal-title":"IDrugs"},{"key":"10.1016\/j.antiviral.2013.11.008_b1055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00928361","article-title":"Physiological concentrations of purines and pyrimidines","volume":"140","author":"Traut","year":"1994","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.antiviral.2013.11.008_b1060","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1021\/ja00848a042","article-title":"4\u2032-Substituted nucleosides. I. Synthesis of 4\u2032-methoxyuridine and related compounds","volume":"97","author":"Verheyden","year":"1975","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2013.11.008_b1065","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/AAC.01335-10","article-title":"INX-08189, a phosphoramidate prodrug of 6-O-methyl-2\u2032-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties","volume":"55","author":"Vernachio","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b1070","unstructured":"Vertex, 2011. Vertex and alios biopharma announce exclusive worldwide licensing agreement for two nucleotide drug candidates, broadening vertex\u2019s efforts to develop new combinations of medicines for hepatitis C. Press release. Retrieved from: <http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=584023>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1075","unstructured":"Vertex, 2012a. Vertex announces collaboration with janssen to initiate phase 2 all-oral study of VX-135 and simeprevir (TMC435) for the treatment of hepatitis C. Press release. Retrieved from: <http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=717772>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1080","unstructured":"Vertex, 2012b. Vertex announces new data on ALS-2200 in people with hepatitis C, supporting advancement into phase 2 all-oral studies in 2012; ends development of ALS-2158. Press release. Retrieved from: <http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=709250>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1085","unstructured":"Vertex, 2012c. Vertex enters agreement with Bristol\u2013Meyers Squibb for phase 2 all-oral studies of VX-135 in combination with daclatasvir for the treatment of Hepatitis C. Press release. Retrieved from: <http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=754494>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1090","unstructured":"Vertex, 2012d. Vertex enters agreement with GlaxoSmithKline for phase 2 all-oral study of VX-135 and GSK2336805 for the treatment of hepatitis C. Press release. Retrieved from: <http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=717777>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1095","unstructured":"Vertex, 2013. Vertex provides update on ongoing all-oral studies of VX-135 in hepatitis C. Press release. Retrieved from: <http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=780456>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jlac.18591120207","article-title":"Acetylderivate der Phloretin und Salicyls\u00e4ure","volume":"112","author":"Von Gilm","year":"1859","journal-title":"Ann. Chem. Pharma."},{"key":"10.1016\/j.antiviral.2013.11.008_b1105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.meegid.2012.12.004","article-title":"RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs","volume":"14","author":"Waheed","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.antiviral.2013.11.008_b1110","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1021\/jo901345j","article-title":"An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase","volume":"74","author":"Wang","year":"2009","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2013.11.008_b1115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep.26274","article-title":"PROPEL: a randomized trial of mericitabine plus peginterferon alfa-2a\/ribavirin therapy in treatment-na\u00efve HCV Genotype 1\/4 patients","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.11.008_b1120","unstructured":"WHO, 2012. Hepatitis C. Fact sheet #164. Retrieved from: <http:\/\/www.who.int\/mediacenter\/factsheet\/fs164\/en\/>."},{"key":"10.1016\/j.antiviral.2013.11.008_b1125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1503\/cmaj.1030034","article-title":"Hepatitis C: a review for primary care physicians","volume":"174","author":"Wong","year":"2006","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.antiviral.2013.11.008_b1130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/AAC.01101-10","article-title":"Safety and Pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects","volume":"55","author":"Zhou","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.11.008_b1135","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1016\/S0168-8278(09)60968-5","article-title":"IDX184, a liver-targeted nucleotide HCV polymerase inhibitor: results of a first-in-man safety and pharmacokinetic study","volume":"50","author":"Zhou","year":"2009","journal-title":"J. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213003392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213003392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T20:59:36Z","timestamp":1564865976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213003392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":227,"alternative-id":["S0166354213003392"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.11.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chutes and ladders in hepatitis C nucleoside drug development","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}